Paper Details

  1. Home
  2. Paper Details

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors.

Author: BalmañaJudith, BorrowJen, BurrisHoward A, ChenLee-May, DomchekSusan M, DrewYvette, GiordanoHeidi, GobleSandra, IsaacsonJeff, KristeleitRebecca, LoRussoPatricia, MaloneyLara, MontesAna, OzaAmit M, PatelManish R, RolfeLindsey, SafraTamar, Shapira-FrommerRonnie, ShapiroGeoffrey I, XiaoJim

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rucaparib is a PARP inhibitor that is used to treat certain types of cancer, including ovarian cancer. This study evaluated the safety and efficacy of oral rucaparib in patients with advanced solid tumors. The study found that rucaparib was well tolerated and had promising activity in patients with platinum-sensitive, high-grade ovarian carcinoma associated with BRCA1/2 mutations.
Paper Details　
Original Abstract of the Article :
<b>Purpose:</b> Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.<b>Experimental Design:</b> Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-16-2796

データ提供：米国国立医学図書館（NLM）

Rucaparib: A Promising PARP Inhibitor for BRCA1/2-Mutated Ovarian Cancer

This study investigates the effectiveness of rucaparib, an oral PARP inhibitor, in treating patients with germline BRCA1/2-mutated ovarian cancer. It's like exploring a vast desert of knowledge, searching for new weapons to fight this challenging disease. The researchers conducted a phase I-II clinical trial to determine the optimal dose and safety profile of rucaparib. The results showed that rucaparib was well-tolerated and demonstrated significant activity in patients with platinum-sensitive, BRCA1/2-mutated ovarian cancer. The study highlighted the potential of rucaparib as a targeted therapy for this specific group of patients.

Rucaparib: A Targeted Therapy for BRCA1/2-Mutated Ovarian Cancer

The study revealed that rucaparib was well-tolerated and exhibited significant activity in patients with platinum-sensitive, BRCA1/2-mutated ovarian cancer. This finding suggests that rucaparib could be a valuable treatment option for these patients, offering potential for improved outcomes and quality of life. It's like discovering a hidden oasis in the desert, providing a source of hope for patients seeking effective treatment for this challenging disease.

New Hope for Ovarian Cancer Patients: A Personalized Approach

This research highlights the importance of personalized medicine, tailoring treatment approaches to the specific genetic characteristics of each patient. By targeting specific mutations, such as BRCA1/2 mutations in ovarian cancer, we can develop more effective and less toxic therapies, improving the lives of patients with this disease. It's like providing a camel with a customized oasis, tailored to its specific needs and preferences, ensuring its well-being in the harsh desert environment.

Dr.Camel's Conclusion

This research provides a promising new treatment option for patients with BRCA1/2-mutated ovarian cancer. Rucaparib, a PARP inhibitor, has shown significant activity and a favorable safety profile in these patients. This discovery is a testament to the power of personalized medicine, where therapies are tailored to the unique genetic characteristics of each individual. It's like providing a camel with a customized oasis, ensuring its survival and well-being in the vast and challenging desert landscape.

Date :
  1. Date Completed 2018-04-23
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

28264872

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-16-2796

Related Literature

Article Analysis
・Side Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.